Cardiovascular Research Center, Mount Sinai School of Medicine, New York, New York, USA.
Address correspondence to: Roger J. Hajjar, Cardiovascular Research Center, Mount Sinai School of Medicine, One Gustave Levy Place, Box 1030, New York, New York 10029, USA. Phone: 212.241.4082; Fax: 212.241.4080; E-mail: email@example.com.
First published January 2, 2013 - More info
Advances in understanding the molecular basis of myocardial dysfunction, together with the evolution of increasingly efficient gene transfer technology, make gene-based therapy a promising treatment option for heart conditions. Cardiovascular gene therapy has benefitted from recent advancements in vector technology, design, and delivery modalities. There is a critical need to explore new therapeutic approaches in heart failure, and gene therapy has emerged as a viable alternative. Advances in understanding of the molecular basis of myocardial dysfunction, together with the development of increasingly efficient gene transfer technology, has placed heart failure within reach of gene-based therapy. The recent successful and safe completion of a phase 2 trial targeting the cardiac sarcoplasmic/endoplasmic reticulum Ca2+ ATPase pump (SERCA2a) has the potential to open a new era for gene therapy for heart failure.
Cardiovascular disease is the leading cause of death in the United States (1). Despite significant advancements in promoting cardiovascular health with therapeutic agents and devices as well as improved understanding of the molecular pathways underlying cardiovascular disease, nearly 20 million Americans are diagnosed with coronary heart disease and congestive heart failure (1).
While progress in conventional treatment modalities is making steady and incremental gains to reduce cardiovascular disease burden, an urgent need to explore new therapeutic approaches remains. Gene therapy, which was initially envisioned as a treatment strategy for inherited monogenic disorders, has broad therapeutic potential, including treatment of acquired polygenic diseases such as peripheral vascular disease, ischemic heart disease, arrhythmias, and congestive heart failure (2). Improved understanding of the molecular basis of these conditions, together with the evolution of increasingly safe and efficient gene transfer technologies, has placed cardiovascular disease within reach of gene-based therapies (2).
This Review focuses on gene-modifying strategies that target diseases of the cardiovascular system. The efficacy of various gene and vector delivery systems is addressed with results from human clinical trials. While there are many promising strategies to modify cardiovascular disease, only molecular targets that have progressed to preclinical and human clinical trials are systematically reviewed here. The cardiologist will benefit from an improved understanding the techniques and rationale behind cardiovascular gene therapy as this therapeutic strategy enters the clinical realm.
The development of cardiovascular gene transfer intervention necessitates addressing several factors to ensure high efficiency while minimizing toxicity (2). These include understanding target cell and transgene biology and the temporal and spatial patterns of the specific cardiovascular pathophysiological process. In addition, the choices of gene and vector delivery systems also critically determine clinical outcomes. Answering these questions will dictate the proportion of target cells within the myocardium that need to be successfully gene modified in order to elicit cardioprotection. Restoring myocardial contractility in the context of heart failure requires successful gene transfer to a vast majority of cardiomyocytes in the ventricular myocardium in order to enable a significant effect on ventricular function. Furthermore, the required temporal pattern of transgene expression will determine the choice of gene transfer system that can be employed for efficient and positive results. Gene delivery systems can be classified into two categories, nonviral systems and recombinant viral systems, each of which have unique profiles in gene transfer expression and their own advantages and disadvantages (Figure 1). Nonviral vectors include naked plasmid DNA, liposomal DNA complexes, polymer-carried DNA, and oligonucleotides. Plasmids are double-stranded circular DNA-containing transgenes encoding proteins of interest, and also have enhancer and promoter sequences (2).
The various vectors commonly used in cardiovascular applications, and their specific characteristics.
Viral vectors from the family Retroviridae include retrovirus and lentivirus (3, 4). Retroviruses contain single-stranded, positive-sense RNAs that utilize a virally encoded reverse transcriptase to generate double-stranded DNA. In order to enable viral DNA integration into the host cell genome, the host cell nuclear membrane must be broken down, as occurs during cell division; retroviruses are therefore limited to infecting dividing cells and cannot efficiently transduce most cardiomyocytes. Lentiviral vectors, also from the family Retroviridae, are single-stranded RNA viruses utilizing reverse transcriptase and genome integration for the long-term expression of transgenes (4). However, lentiviral vectors are capable of transducing mitotically quiescent cells, allowing for efficient transduction of cardiomyocytes. The random integration afforded by the lentivirus continues to be a concern.
An adenovirus is a non-enveloped, non-integrating virus containing double-stranded DNA with two main transcriptional regions, early and late phase. The early phase encodes E1, E2, E3, and E4 viral proteins, which are necessary for activating the S phase of the cell cycle, DNA polymerase, and splicing proteins. The E1–E4 proteins elicit a significant innate immune response, which is the major therapeutic challenge in using adenoviruses in human applications. Third-generation “gutless” adenoviral vectors with deleted E1–E4 proteins have a lower immunogenicity profile and partially overcome this obstacle (5). In the heart, adenoviral transgene expression is robust but transient (6). Transgene expression levels peaks within two to three days and return to undetectable levels by two weeks. This imposes therapeutic challenges for chronic pathological processes such as congestive heart failure but may be appropriate for short-term, pro-angiogenic responses.
Adeno-associated viruses (AAVs) are members of the family Parvoviridae and are non-enveloped, single-stranded DNA viruses (7). AAVs are relatively small (20 nm) and therefore are limited in their genome capacity of 4.7 kb. There are 13 reported serotypes of AAV with varying degrees of tissue tropism, depending on capsid protein structure (7). AAV1, -6, -8, and -9 have been identified as being the most cardiotropic, but significant transduction persists in nontarget tissues such as liver, skeletal muscle, and lung. Neutralizing antibodies to various AAV serotypes are present in approximately 20%–80% of the population, therefore severely limiting the potential therapeutic use of AAVs, and are a major exclusion criteria in many AAV-based clinical trials (8, 9).
The various vector systems all have different expression kinetics and tissue tropisms that must be taken into account when designing human gene therapy trials. Nonspecific expression and off-target effects are an obstacle for any therapeutic modality.
The selection of the appropriate vector delivery method is critical for proper implementation of the therapeutic strategy and for efficient transgene expression in the myocardium (10, 11). Vectors have unique profiles of bioavailability, transgene expression kinetics, and tissue tropisms, and it is therefore vital to choose a vector delivery method that complements the vector as well as the disease process. Importantly, the invasiveness of the vector delivery method and patient safety require critical assessment prior to initiating gene therapy trials for cardiovascular disease (10, 11).
Percutaneous coronary artery catheterization is a minimally invasive and well-established procedure that allows homogeneous gene delivery to each territory of the heart. This approach is relatively safe, making it especially attractive for patients with end-stage heart failure. However, gene delivery can be impeded in patients with severe coronary artery disease. More importantly, some variability regarding the efficiency of antegrade coronary gene transfer exists and is partly related to the relatively fast transit of the vector through the vasculature (ref. 12 and Figure 2).
Infusion-based techniques for gene delivery to the heart. (A) Coronary artery infusion. The vector is injected through a catheter, without interruption of the coronary flow, using a slow infusion. (B) Retrograde coronary venous infusion with simultaneous blocking of a coronary artery and a coronary vein. The vector is injected into a coronary vein and resides in the coronary circulation until both balloons are deflated.
Enhanced vector residence time in the coronary circulation is achievable with coronary venous blockade. Antegrade coronary infusion with a short occlusion of both a coronary artery and a coronary vein enhanced myocardial gene expression (13, 14). This method preserved LV function and inhibited ventricular remodeling in a large animal model of heart failure (14). However, even a short ischemia period carries risk in patients with advanced heart failure.
To maximize the duration of vector exposure to the endothelium while minimizing systemic distribution, Kaye et al. developed a cardiac recirculation approach (15). They engineered an extracorporeal device that drains blood from the coronary sinus using an occlusion catheter and returns the oxygenated coronary venous blood to the left main coronary artery via a peristaltic pump (V-Focus; Osprey Medical Inc.) (16, 17). In an ovine model of tachycardia-induced heart failure, the closed-loop recirculation method was more efficient in the transduction of cardiomyocytes than antegrade coronary infusion, which also translated into a greater improvement of LV function (15, 16). In addition, this method allows the selective administration of endothelial permeabilizing agents (18) without systemic side effects.
Most approaches to improve the efficiency of coronary artery infusion are based on increasing the exposure time of the vector to the endothelium. However, transduction efficacy correlates with coronary flow as well as exposure time and vector concentration (19). Based on the former, antegrade coronary artery infusion supported by an increased coronary flow, for example an intra-aortic balloon pump, might further enhance cardiac gene transfer (20). Antegrade coronary artery infusion might be the safest percutaneous gene delivery method, but at the cost of efficiency relative to other techniques. However, to date, all optimization strategies implicate potential damage to the myocardium, limiting their clinical application.
The coronary venous system provides an alternate route for the percutaneous delivery of therapeutic agents to the myocardium. In a clinical setting, this approach is attractive for patients with impaired coronary artery circulation and limited potential for revascularization. Access to the myocardium can be achieved with this approach regardless of atherosclerosis severity or coronary artery obstruction. Numerous studies showed that retrograde coronary venous infusion is an alternate myocardial delivery method for cardioprotective drugs (21, 22). Shortly thereafter, retrograde venous infusion was also explored as a method for gene transfer. The rationale for a high transduction efficiency is based on controlling the exposure time of the vector to the endothelium and on increasing the pressure gradient of capillary filtration (23, 24).
Studies in large animal models demonstrated that an efficient and homogeneous myocardial transduction can be achieved by retroinfusion into the coronary venous system (24–26). Boekstegers et al. showed that gene expression after pressure-regulated retrograde venous infusion was significantly higher than after antegrade coronary delivery if the retroinfusion was accompanied by simultaneous induced ischemia (ref. 24 and Figure 2B). Compared with percutaneous or surgical direct myocardial injection, retrograde venous infusion also achieved more homogeneous and efficient reporter gene expression (25).
Similar to antegrade coronary artery infusion, a closed loop recirculation retrograde venous infusion approach is also feasible (27). Recently, White et al. demonstrated an extremely high transduction efficiency in the majority of cardiomyocytes in sheep while minimizing collateral organ exposure using a retrograde recirculation method during cardiopulmonary bypass surgery (28). Retrograde coronary infusion has been shown to be safe, when performed by a trained and experienced surgeon. Trauma to the coronary veins, a potential complication, could be minimized with modifications and improvements in catheter design. However, the procedure is not completely without risks. Highly elevated coronary venous pressure can result in myocardial edema or hemorrhage. Careful pressure monitoring should always be used to avoid this complication. Although, with the growing demand for cardiac resynchronization therapy, cannulation of the coronary veins has become a routine procedure, the monitoring of pressure regulation adds to the complexity of this procedure. More importantly, ischemia during the infusion might not be well tolerated in patients with advanced heart failure. While relatively complex, percutaneous retrograde coronary infusion is an effective and minimally invasive procedure for gene delivery to the myocardium. This approach requires some expertise and meticulous pressure monitoring to be performed safely.
Intramyocardial injection is one of the most widely used gene transfer methods in both small animal studies as well as clinical trials focused on cardiac angiogenesis. The vectors are injected either epicardially (Figure 3A) or endocardially (Figure 3B) into the target area with a small-gauge needle. The primary advantage of this method is that vector delivery bypasses the endothelial barrier. This results in a high local concentration at the injection site. In addition, by avoiding exposure to the blood, deactivation of the vectors by circulating DNases or neutralizing antibodies can be prevented. Furthermore, there is minimal exposure of the vector to off-target organs, although local administration cannot completely avoid some systemic vector distribution (29, 30). Low volumes at high vector concentrations may increase the vector retention in the myocardium (29).
Direct myocardial injection and pericardial injection methods of gene delivery. (A) Percutaneous myocardial injection. The vector is injected with an injection catheter via an endocardial approach. (B) Surgical myocardial injection. The vector is injected via an epicardial approach. (C) Percutaneous pericardial injection; the vector is injected in the pericardial space.
The simplest approach, however invasive, is the injection during the thoracotomy (31). Surgical delivery offers direct visual confirmation, which allows precise control of the injection site, including an infarct border.
The endocardial approach requires a catheter with a retractable injection needle and imaging guidance modality for determining the injection site (30). This includes electrical mapping systems (32), fluoroscopy (33), echocardiography (34), and magnetic resonance imaging (35). Currently, the NOGA electromechanical mapping system is the most commonly used guiding system that is also used in clinical angiogenesis trials.
Intramyocardial injection is attractive for local gene delivery. However, the application of this method for heart failure, which is associated with global impairments in cardiomyocytes, might be limited by a circumscribed target area and inhomogeneous expression profiles (25, 31).
Intrapericardial delivery is performed surgically in rodents (36), whereas a percutaneous approach is also possible in larger animals (Figure 3C). The percutaneous pericardial puncture has been proven to be feasible and safe when guided by imaging techniques such as fluoroscopy and intravascular ultrasound. The percutaneous access to the pericardial space can be minimally invasive via a substernal/xhiphoidal puncture. A transatrial approach has also been described (37), but this technique can result in more fibrosis and scar tissue compared with the substernal approach.
The pericardial space faces most of the cardiac wall, except the septum. In heart failure, in which widespread cardiac gene transfer with little systemic distribution is desired, this large-scale interface combined with the concept of a closed compartment can be a major advantage. These features potentially enable prolonged vector persistence, a slow release over time, a high vector concentration, and minimal leakage to nontarget organs. However, tightly joined pericardial cells restrict transfection to superficial myocardial layers (36, 38, 39). This limitation can be partly overcome by the co-administration of various pharmacological agents. Proteolytic enzymes and polyethyleneimine have been shown to increase the penetration depth of the vectors and to allow progressive release, often at the cost of cardiac toxicity (36, 40). Although vectors are injected into a closed space, some studies reported extracardiac gene expression, probably due to the rapid turnover of the pericardium fluid through the lymphatic absorption (41). A platform that allows slow vector release together with a permeabilizing, nontoxic agent may increase the potential of pericardial injection for gene delivery (42).
The combination of echocardiography contrast microbubbles with a viral vector delivery system has been shown to provide efficient gene transduction to the myocardium (43, 44). However, there is some concern that microbubble destruction by echocardiography can cause endothelial damage.
Over the last 20 years, there has been significant evolution in our understanding of the pathophysiology of heart failure in its molecular and cellular dimensions, thus leading to a broader scope of interventions available for gene therapy. For targets to be validated, it is important that they rescue function in animal models in which heart failure has been already established, that the rescue is not associated with arrhythmogenesis, and that a gene-dose effect is established (i.e., with increasing gene expression, a concomitant improvement in function is observed). Excitation-contraction coupling is dysregulated at multiple levels in the development of heart failure. For this reason, the various channels, transporters, and critical proteins have been targeted pharmacologically and by genetic editing to restore contractile function. In Figure 4, the various targets in excitation-contraction coupling are presented.
Excitation-contraction coupling in cardiomyocytes, with multiple targets for genetic modulation. Strategies for improving calcium cycling within the cardiac cell have focused on pharmacologically inhibiting the Na/K ATPase, which results in increased intracellular Ca2+; more recently, strategies have focused on stabilizing the RYR, resulting in decreased sarcoplasmic reticulum Ca2+ leak. Gene editing techniques have focused on enhancing the activity of SERCA2a by either increasing the level of SERCA2a or altering the expression of its partners.
Targeting the β-adrenergic system. The β-adrenergic signaling is adversely affected by multiple changes that lead to β-adrenergic receptor (β-AR) downregulation and de-sensitization. Upregulation of the critical protein G protein–coupled receptor kinase 2 (GRK2) seems to precipitate the abnormalities in β-AR signaling abnormalities. Several gene-based experiments have tested the hypothesis that genetic manipulation of the myocardial β-AR system can enhance cardiac function.
Overexpression of β-AR was initially tested as a simple way to overcome β-AR downregulation. Transgenic mice overexpressing the human β1-ARs suffered from severe cardiomyopathy (45). In contrast, mice with cardiac overexpression of β2-AR demonstrated increased basal myocardial adenylyl cyclase activity with increased LV function (46). Both direct and intracoronary myocardial delivery of adenovirus containing the human β2-AR transgene resulted in enhanced cardiac performance in rodents and mammalian models (47, 48).
The interaction between activated β-ARs and G proteins is regulated by kinases that modulate the receptor activity by phosphorylation of its carboxyl terminus. Agonist-dependent desensitization is mediated by a family of GRKs that phosphorylate the agonist-occupied receptors, resulting in functional uncoupling. GRK2 binds to the Gβγ subunit of activated G proteins, phosphorylating β-ARs that subsequently attach to the inhibitory protein β-arrestin. GRK2, the most abundantly expressed GRK in the heart, has been implicated in the pathogenesis of dysfunctional cardiac β-AR signaling, accounting for a deleterious activity in the failing heart (49). In mice, selective GRK2 ablation following myocardial infarction–induced heart failure resulted in increased survival, halted ventricular remodeling, and enhanced cardiac contractile performance (50). βARKct, a peptide capable of inhibiting GRK2 mediated β-AR desensitization, has been evaluated in vivo in animals. Using intracoronary adenovirus-mediated βARKct transgene delivery to rabbits three weeks after induced myocardial infarction demonstrated a marked reversal of ventricular dysfunction (51). More recent studies have focused on overexpressing βARKct in large animal models (52).
Although detrimental outcomes were demonstrated with multiple elements of the β-adrenergic system used to improve the expression of cAMP, activation of adenylate cyclase 6 (ADCY6) seems to have a unique and favorable profile. Overexpression of ADCY6 in transgenic mice resulted in improved cardiac function in response to adrenergic stimulation along with increased cAMP production in isolated cardiomyocytes. Importantly, ADCY6 had a neutral effect on basal heart function and was not associated with any structural heart abnormalities (53). In a pacing model of heart failure in pigs, intracoronary delivery of adenovirus encoding ADCY6 resulted in improved LV function and remodeling, associated with increased cAMP-generating capacity (54). The favorable effects of ADCY6 in preclinical studies are encouraging, and this approach is currently under investigation for initiation of clinical trials in patients with heart failure (55).
Targeting Caβ+ cycling proteins. Heart failure is characterized by multiple defects in Caβ-handling proteins involved in excitation-contraction coupling (Figure 4). Reversal of those defects by gene therapy techniques has shown very promising results.
More than 20 years ago, Gwathmey et al. first reported that calcium cycling is abnormal in human heart failure (56); this is partially due to decreased sarcoplasmic/endoplasmic reticulum Ca2+ ATPase 2a (SERCA2a) activity regardless of the etiology of the heart failure (57–60). Improvement in cardiac contractility after gene transfer of SERCA2a has been demonstrated in a large number of experimental models of heart failure (61, 62). More importantly, long-term overexpression of SERCA2a by intracoronary delivery of AAVs carrying SERCA2a was associated with preserved systolic function and improved ventricular remodeling in a swine model of volume-overload heart failure (63). Beyond their effects on enhancing contractility, SERCA2a gene transfer has been shown to (a) restore the normal state of cardiac energetics (64, 65) in terms of energy supply and utilization, (b) decrease ventricular arrhythmias (66–69), and (c) enhance coronary flow through activation of eNOS in endothelial cells (70).
Another approach to improve Caβ+ handling involves inhibition of phospholamban (PLN). The lowering of PLN levels in human cardiomyocytes resulted in improved contraction and relaxation velocities similar to the benefit seen with gene transfer of SERCA2a (71). Silencing of PLN expression in a sheep model of heart failure resulted in improved SERCA activity along with improved systolic and diastolic LV function (15). In addition to the above conventional gene therapy strategies, RNAi therapy was used for the first time in a model of cardiac disease, specifically in rats with heart failure, in an attempt to suppress PLN expression. An AAV9 RNAi vector generated stable cardiac production of a regulatory RNA sequence, which in turn suppressed PLN expression. SERCA2a protein levels were subsequently increased, accompanied by the restoration of systolic and diastolic cardiac function (72).
Heart failure is also associated with elevated protein phosphatase 1 (PP1) activity in humans, which results in dephosphorylation of PLN. Overexpression of PP1 or ablation of inhibitor of PP1 (I-1) in murine hearts has been associated with decreased β-AR–mediated contractile responses, depressed cardiac function, and premature death consistent with heart failure (73–75). Expression of a constitutively active I-1 in transgenic mice led to PP1 inhibition with increased phosphorylation of PLN and improved cardiac contractility. A recent study on transgenic mice expressing active I-1 confirmed the relationship between phosphorylation of PLN and SERCA2a activity. I-1 expression ameliorated ischemia/reperfusion-induced injury by reducing the infarct size and improving contractile recovery in addition to decreasing biomarkers of apoptosis and ER stress response (73–75).
S100 is part of a family of Caβ+-modulated proteins implicated in intracellular regulatory activities. S100A1 is the most abundant S100 protein isoform in the heart. It promotes cardiac contractile and relaxation function by enhancing the activity of both ryanodine receptors (RYRs) and SERCA2a (76). In a rat model of heart failure, AAV6-mediated long-term expression of S100A1 resulted in a sustained in vivo reversal of LV dysfunction and remodeling (77, 78). More recently AAV9 gene transfer of S100A1 in a preclinical model of ischemic cardiomyopathy induced dramatic improvements in contractile function, reinforcing the rationale that a clinical trial of S100A1 gene therapy for human heart failure should be forthcoming.
Recently Kho et al. reported that the levels and activity of SERCA2a in cardiomyocytes are modulated in parallel with the levels of small ubiquitin-related modifier 1 (SUMO1) (79). SUMOs are a family of peptides that broadly alter the function of other proteins in cells through a post-translational modification known as sumoylation. Kho et al. found that sumoylation enhances the stability of SERCA2a in the cell as well as increases its activity. SUMO1 levels were reduced in murine and pig models of heart failure and in failing human ventricles. Increasing SUMO1 levels by AAV9 gene transfer led to a restoration of SERCA2a levels, improved hemodynamic performance, and reduced mortality among the animals with heart failure.
Lastly, the SDF1/CXCR4 complex has emerged as a therapeutic target in ischemic heart failure (80) due to the ability of the SDF1/CXCR4 system to promote the homing of stem cells to infracted myocardium. A clinical trial is underway to investigate the therapeutic benefit of SDF1 overexpression in ischemic cardiomyopathy (81). In parallel, existing literature highlights the direct effects of CXCR4 on the myocardium and the cardiomyocyte. SDF1 was shown to decrease myocardial contractility ex vivo and on cardiomyocytes (82). One recent report has shown increased ischemia-reperfusion injury in rat hearts overexpressing CXCR4 (83), while another report investigated the modulation of β-AR signaling by SDF1 and CXCR4 (84), raising interrogations over the potential complex interaction between these chemokines and the cardiovascular system.
After years of consecutive failures, gene therapy trials for specific monogenic diseases have shown some successes, most notably for inherited blindness in a pediatric patient with Leber congenital amaurocis (85) and in hemophilia.
The first clinical trial of gene therapy in patients with heart failure was launched in the United States in 2007 (86, 87). Calcium Up-regulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID) was a two-part, Phase 1/2 multicenter trial designed to evaluate the safety and the biological effects of gene transfer of the SERCA2a cDNA by delivering a recombinant AAV1 (AAV1.SERCA2a) in patients with advanced heart failure. In part 1, participants in this trial were administered a single intracoronary infusion of AAV1.SERCA2a in an open-label approach (86, 87). Four cohorts of three patients each received a single escalating dose of AAV1.SERCA2a. Twelve-month follow-up of these patients showed an acceptable safety profile (86, 87). Improvement was detected in several patients, as reflected by symptomatic (five patients), functional (four patients), biomarker (two patients), and LV function/remodeling (six patients) parameters. Although part 1 was a phase 1 study involving a small number of patients, the results suggested that AAV1.SERCA2a treatment confers quantitative biological benefit.
In part 2 of the trial, 39 patients with advanced heart failure were randomized to receive intracoronary AAV1-mediated SERCA2a gene delivery in one of three doses (low dose: 6 × 1011 DRP, middle dose: 3 × 1012 DRP, and high dose: 1 × 1013 DRP) or placebo (88). Patients’ symptoms (New York Heart Association (NYHA) classification and Minnesota Living With Heart Failure Questionnaire [MLWHFQ] score), functional status (six-minute walk test [6MWT] and VO2 max), NT-proBNP levels, and echocardiographic measures were evaluated over six months. Treatment success was determined by evaluating clinical outcomes and concordant trends in the above endpoints for group- and patient-based comparisons. The AAV1.SERCA2a high-dose group met the pre-specified criteria for success at the group and individual patient levels. Compared with patients treated with placebo, those treated with AAV1.SERCA2a demonstrated improvement or stabilization in NYHA class, MLWHFQ, 6MWT, VO2 max, NT-proBNP levels, and LV end-systolic volumes at 12 months. Over a one-year period, cumulative recurrent cardiovascular events (death, heart failure admission, LV assist device insertion, cardiac transplantation, and myocardial infarction) increased in the placebo group, as shown in Figure 5. The low- and middle-dose AAV1.SERCA2a groups had diminished recurrent cardiovascular events for the first six months, and from months 6 to 12 had events that were similar to placebo. The high-dose AAV1.SERCA2a group, however, continued to do significantly better than all groups at 12 months, as shown in Figure 5. No increases in adverse events, disease-related events, laboratory abnormalities, or arrhythmias were observed in AAV1.SERCA2a-treated patients compared with placebo (88).
Cumulative clinical event rates, adjusted for the competing risk of terminal events, in patients followed for 12 months in the phase 2 segment of the CUPID trial. Modified with permission from Circulation (88).
Two other clinical trials targeting SERCA2a will be enrolling patients soon. The first trial, which is being conducted in the United Kingdom, is in patients with advanced heart failure who received LV assist devices at least one month prior to treatment and who will receive be treated with AAV1.SERCA2a or saline. A phase 2, single-center, double-blind, randomized, placebo-controled, parallel-group study will be conducted at the Institut de Cardiologie Pitié-Salpêtrière in Paris, France, with the primary objective of investigating the impact of AAV1.SERCA2a on cardiac remodeling parameters in patients with severe heart failure.
In another ongoing clinical study that is currently enrolling patients, adenovirus 5–encoding human ADCY6 is delivered through intracoronary injection of Ad5.hAC6 or PBS with dose escalation to patients with congestive heart failure.
An additional trial that is currently recruiting patients will examine the effects of injecting SDF1 directly into the myocardium of patients with ischemic heart disease. In this open-label trial, the safety will be evaluated of an endomyocardial injection of a single escalating dose of SDF1-naked DNA at multiple sites using a percutaneous LV approach, to cohorts of adults with ischemic heart failure.
As our understanding of the molecular mechanisms associated with heart failure has improved and vectors with cardiotropic properties are being developed, gene therapy can now be considered a viable adjunctive treatment to mechanical and pharmacological therapies for heart failure. In the coming years, additional targets will emerge that are amenable to genetic manipulations, as well as more advanced vector systems that will undoubtedly lead to safer and more effective clinical trials in gene therapy for heart failure.
This work is supported by NIH grants R01 HL093183, HL088434, and P20HL100396; Program of Excellence in Nanotechnology contract HHSN26820100045c; and P50HL 112324.
Conflict of interest: R.J. Hajjar is a scientific founder of Celladon Corp., which plans to commercialize AAV1.SERCA2a for the treatment of heart failure.
Reference information: J Clin Invest. 2013;123(1):53–61. doi:10.1172/JCI62837.
Potential of gene therapy as a treatment for heart failure
Roger J. Hajjar
Induced pluripotent stem cell–derived cardiomyocytes in studies of inherited arrhythmias
Silvia G. Priori et al.
Signaling effectors underlying pathologic growth and remodeling of the heart
Jop H. van Berlo et al.
S-nitrosylation: integrator of cardiovascular performance and oxygen delivery
Saptarsi M. Haldar et al.
Genetic mutations and mechanisms in dilated cardiomyopathy
Elizabeth M. McNally et al.
Myocardial ischemia-reperfusion injury: a neglected therapeutic target
Derek J. Hausenloy et al.
New approaches under development: cardiovascular embryology applied to heart disease
Karl Degenhardt et al.
Molecular and genetic basis of sudden cardiac death
Alfred L. George Jr.
Regenerating new heart with stem cells
Piero Anversa et al.
Adaptive immunity in atherogenesis: new insights and therapeutic approaches
Andrew H. Lichtman et al.